AstraZeneca’s (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

The European Commission approves AstraZeneca’s (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.